Webinars: Insights on Duchenne muscular dystrophy (DMD) from leading experts.
In this webinar, Sarepta Therapeutics presents an update on their Duchenne muscular dystrophy pipeline. Diane Berry, PhD, Senior Vice President, Global Health Policy, Government and Patient Affairs and Louise Rodino-Klapac, […]
During this webinar, you will learn about NS Pharma, Inc. (a wholly owned, US subsidiary of Nippon Shinyaku Co., Ltd. based in Kyoto, Japan), focused on developing innovative treatments for […]
Part 1 of the series engages families who have recently begun their Duchenne journey, or those who could benefit from introductory-level presentations on the following topics: Message From A Duchenne […]
CureDuchenne cornered the best and brightest to gather relevant information for people living with Duchenne. Tiffany Cook asks the questions you’ve been thinking – from experts in their field who […]
Descripción: Un evento virtual de dos horas centrado en la información sobre COVID-19 y los recursos en el hogar para las personas que viven con Duchenne. Seminario web de Zoom: Abierto al público, dirigido a la comunidad de Duchenne de habla hispana Panelistas: Dr. […]
In this webinar, moderated by Tiffany Cook, MS, CCC-SLP, Senior Director of CureDuchenne Cares, the mental health presentation by Paige Lembeck, PhD, will be followed by several presentations from biopharmaceutical companies […]
In this webinar, Beth Belluscio, MD, PhD, Pfizer Global Clinical Lead for Rare Neurological Disorders, discusses the Phase 3 study of PF-06939926, a gene therapy for Duchenne muscular dystrophy. Dr. Belluscio answers questions […]
In this webinar, Sarepta Therapeutics discusses their patient support program, SareptAssist, intended to support individuals through the process of starting and staying on commercial therapy. Services provided by SareptAssist include […]
Suvodirsen (formerly known as WVE-210201) is an investigational stereopure oligonucleotide being developed as a potential treatment for boys with Duchenne muscular dystrophy with mutations amenable to exon 51 skipping. Wave […]
